Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04294472 · ClinicalTrials.gov registry record · Phase 2
A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
A Phase 2 study, sponsored by Vera Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04294472 is a Phase 2 study that has completed, run by Vera Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT04294472, a Phase 2 study, has completed, sponsored by Vera Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This clinical research study will test the safety and efficacy of the investigational medication MAU868, compared to a placebo, in patients who have had a kidney transplant who have active BK virus.
Interventions
- OTHER Placebo
- DRUG MAU868
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2022-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04294472
The ClinicalTrials.gov registry entry for NCT04294472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vera Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04294472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04294472 about?
NCT04294472 is a clinical study titled "A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients". This clinical research study will test the safety and efficacy of the investigational medication MAU868, compared to a placebo, in patients who have had a kidney transplant who have active BK virus.
What is the current status of trial NCT04294472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-08-05. Estimated completion is 2022-02-10.
What interventions are being tested in trial NCT04294472?
The interventions under investigation include: Placebo (OTHER), MAU868 (DRUG).
Who is sponsoring clinical trial NCT04294472?
This trial is sponsored by Vera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.